The changes of immune function after neuroblastoma chemotherapy and the prediction of potential immune targets
This study combines proteomics and bioinformatics to predict and explore potential immune targets for synergistic chemotherapy against neuroblastoma, providing a new direction for clinical treatment that warrant further validation.
Authors
- Yan Su (ORCID: https://orcid.org/0000-0002-1546-2799)
- Xin Ni (ORCID: https://orcid.org/0000-0002-7781-2600)
- Sheng‐Jie You (ORCID: https://orcid.org/0000-0003-0532-9916)
- Jing Huang (ORCID: https://orcid.org/0000-0001-7593-0980)
- Yunfei Ma (ORCID: https://orcid.org/0000-0002-8295-630X)
- Wen Zhao (ORCID: https://orcid.org/0000-0002-6329-5913)
- Cheng Huang (ORCID: https://orcid.org/0000-0002-9183-3547)
- Hu Yan (ORCID: https://orcid.org/0009-0008-2124-3868)
- Jing Qin
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Xiyuan Hospital (CN)
- Beijing Children’s Hospital (CN)
Publication Details
- Journal
- BMC Medical Genomics
- Published
- 2025-08-20
- DOI
- https://doi.org/10.1186/s12920-025-02185-6
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China